Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
McKesson
Dow
Harvard Business School
Mallinckrodt

Last Updated: May 27, 2022

ADVIL ALLERGY SINUS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Advil Allergy Sinus patents expire, and what generic alternatives are available?

Advil Allergy Sinus is a drug marketed by Glaxosmithkline and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in eighteen countries.

The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Advil Allergy Sinus

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 28, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for ADVIL ALLERGY SINUS
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ADVIL ALLERGY SINUS?ADVIL ALLERGY SINUS excipients list
DailyMed Link:ADVIL ALLERGY SINUS at DailyMed
Drug patent expirations by year for ADVIL ALLERGY SINUS
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ADVIL ALLERGY SINUS
Generic Entry Date for ADVIL ALLERGY SINUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for ADVIL ALLERGY SINUS
C01CA Adrenergic and dopaminergic agents
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01 CARDIAC THERAPY
C Cardiovascular system
C01EB Other cardiac preparations
C01E OTHER CARDIAC PREPARATIONS
C01 CARDIAC THERAPY
C Cardiovascular system
D04AA Antihistamines for topical use
D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D Dermatologicals
G02CC Antiinflammatory products for vaginal administration
G02C OTHER GYNECOLOGICALS
G02 OTHER GYNECOLOGICALS
G Genito-urinary system and sex hormones
M01AE Propionic acid derivatives
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M Musculo-skeletal system
M02AA Antiinflammatory preparations, non-steroids for topical use
M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M Musculo-skeletal system
R01AA Sympathomimetics, plain
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
R01AB Sympathomimetics, combinations excl. corticosteroids
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
R01BA Sympathomimetics
R01B NASAL DECONGESTANTS FOR SYSTEMIC USE
R01 NASAL PREPARATIONS
R Respiratory system
R02AX Other throat preparations
R02A THROAT PREPARATIONS
R02 THROAT PREPARATIONS
R Respiratory system
R03CA Alpha- and beta-adrenoreceptor agonists
R03C ADRENERGICS FOR SYSTEMIC USE
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R Respiratory system
R06AB Substituted alkylamines
R06A ANTIHISTAMINES FOR SYSTEMIC USE
R06 ANTIHISTAMINES FOR SYSTEMIC USE
R Respiratory system
S01FB Sympathomimetics excl. antiglaucoma preparations
S01F MYDRIATICS AND CYCLOPLEGICS
S01 OPHTHALMOLOGICALS
S Sensory organs

US Patents and Regulatory Information for ADVIL ALLERGY SINUS

ADVIL ALLERGY SINUS is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ADVIL ALLERGY SINUS is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ADVIL ALLERGY SINUS

Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ADVIL ALLERGY SINUS chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 021441-001 Dec 19, 2002 OTC Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ADVIL ALLERGY SINUS

When does loss-of-exclusivity occur for ADVIL ALLERGY SINUS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2543
Estimated Expiration: See Plans and Pricing

Australia

Patent: 03301188
Estimated Expiration: See Plans and Pricing

Patent: 05251733
Estimated Expiration: See Plans and Pricing

Patent: 11200912
Estimated Expiration: See Plans and Pricing

Canada

Patent: 08611
Estimated Expiration: See Plans and Pricing

Patent: 68443
Estimated Expiration: See Plans and Pricing

Chile

Patent: 03002653
Estimated Expiration: See Plans and Pricing

China

Patent: 26035
Estimated Expiration: See Plans and Pricing

Patent: 1065112
Estimated Expiration: See Plans and Pricing

Patent: 2406642
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 40087
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 72206
Estimated Expiration: See Plans and Pricing

Patent: 55561
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 78494
Estimated Expiration: See Plans and Pricing

Patent: 66602
Estimated Expiration: See Plans and Pricing

Japan

Patent: 41228
Estimated Expiration: See Plans and Pricing

Patent: 06515299
Estimated Expiration: See Plans and Pricing

Patent: 08501692
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 05006331
Estimated Expiration: See Plans and Pricing

Patent: 06013919
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 0289
Estimated Expiration: See Plans and Pricing

Patent: 2030
Estimated Expiration: See Plans and Pricing

Peru

Patent: 040973
Estimated Expiration: See Plans and Pricing

Patent: 081072
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 72206
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 22262
Estimated Expiration: See Plans and Pricing

Patent: 05122403
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0504908
Estimated Expiration: See Plans and Pricing

Spain

Patent: 68217
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 13598
Estimated Expiration: See Plans and Pricing

Patent: 0413004
Estimated Expiration: See Plans and Pricing

Patent: 0609004
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ADVIL ALLERGY SINUS around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1078494 非甾體抗炎藥、解充血藥和抗組胺藥的組合物 (COMPOSITIONS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DECONGESTANTS AND ANTI-HISTAMINES) See Plans and Pricing
Peru 20081072 COMPOSICIONES DE ANTI-HISTAMINICOS, DESCONGESTIVOS, ANTITUSIVOS Y DROGAS ANTI-INFLAMATORIOS NO ESTEROIDALES See Plans and Pricing
Hong Kong 1166602 COMPOSITIONS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DECONGESTANTS AND ANTI-HISTAMINES See Plans and Pricing
New Zealand 540289 Pharmaceutical compositions of non-steroidal anti-inflammatory drugs (NSAID), decongestants and anti-histamines See Plans and Pricing
European Patent Office 1572206 COMPOSITIONS DE MEDICAMENTS ANTI-INFLAMMATOIRES NON-STEROIDAUX, DECONGESTIONNANTS ET ANTIHISTAMINIQUES (COMPOSITIONS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DECONGESTANTS AND ANTI-HISTAMINES) See Plans and Pricing
Canada 2568443 COMPRIME MULTICOUCHE COMPRENANT DES MEDICAMENTS ANTI-INFLAMMATOIRES NON STEROIDIENS, DES DECONGESTIONNANTS ET DES ANTIHISTAMINIQUES NON SEDATIFS (MULTI-LAYER TABLET COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, DECONGESTANTS AND NON-SEDATING ANTIHISTAMINES) See Plans and Pricing
European Patent Office 1755561 COMPRIME MULTICOUCHE COMPRENANT DES MEDICAMENTS ANTI-INFLAMMATOIRES NON STEROIDIENS, DES DECONGESTIONNANTS ET DES ANTIHISTAMINIQUES NON SEDATIFS (MULTI-LAYER TABLET COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DECONGESTANTS AND NON-SEDATING ANTIHISTAMINES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKesson
Dow
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.